EBP50 gene transfection promotes 5-fluorouracil-induced apoptosis in gastric cancer cells through Bax- and Bcl-2-triggered mitochondrial pathways

Molecular Medicine Reports

Volumn 5, Issue 5, 2012, Pages 1220-1226

  Lv, Xiao Guang ^a   Ji, Meng Yao ^a   Dong, Wei Guo ^a   Lei, Xiao Fei ^a   Liu, Meng ^a   Guo, X U Feng ^a   Wang, Jing ^a   Fang, Chuo ^a  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

5 fluorouracil; Apoptosis; Ezrin radixin moesin binding phosphoprotein 50 gene; Gastric cancer

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; 4 [5 (4 METHYL 1 PIPERAZINYL)[2,5' BI 1H BENZIMIDAZOL] 2' YL]PHENOL; EZRIN RADIXIN MOESIN BINDING PHOSPHOPROTEIN 50; FLUORESCEIN ISOTHIOCYANATE; FLUOROURACIL; LIPOCORTIN 5; MESSENGER RNA; PHOSPHOPROTEIN; PROTEIN BAX; PROTEIN BCL 2; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL GROWTH; CHEMOSENSITIVITY; CONTROLLED STUDY; EBP50 GENE; FLOW CYTOMETRY; GENE; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; MITOCHONDRION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH CANCER; WESTERN BLOTTING;

ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FLUOROURACIL; HUMANS; MITOCHONDRIA; PHOSPHOPROTEINS; SODIUM-HYDROGEN ANTIPORTER; STOMACH NEOPLASMS; TRANSFECTION;

EID: 84863296605     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2012.805     Document Type: Article

References (23)

1. Hartgrink HH, Jansen EPM, Van Grieken NC and van de Velde CJ: Gastric Cancer. Lancet 374: 477-490, 2009.
2. Ajani JA: Evolving chemotherapy for advanced gastric cancer. Oncologist 10: 49-58, 2005.
3. Ohtsu A: Current status and future prospects of chemotherapy for metastatic gastric cancer: a review. Gastric Cancer 8: 95-102, 2005.
4. Longley DB, Harkin DP and Johnston PG: 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 3: 330-338, 2003. (Pubitemid 37328853)
5. Song J, Bai J, Yang W, Gabrielson EW, Chan DW and Zhang Z: Expression and clinicopathological significance of oestrogen-responsive ezrin-radixin-moesin- binding phosphoprotein 50 in breast cancer. Histopathology 51: 40-53, 2007. (Pubitemid 46976376)
6. Bellizzi A, Malfettone A, Cardone RA and Mangia A: NHERF1/EBP50 in breast cancer: clinical perspectives. Breast Care (Basel) 5: 86-90, 2010.
7. Morales FC, Takahashi Y, Momin S, et al: NHERF1/EBP50 head-to-tail intramolecular interaction masks association with PDZ domain ligands. Mol Cell Biol 27: 2527-2537, 2007. (Pubitemid 46581344)
8. Schindelmann S, Windisch J, Grundmann R, Kreienberg R, Zeillinger R and Deissler H: Expression profiling of mammary carcinoma cell lines: correlation of in vitro invasiveness with expression of CD24. Tumour Biol 23: 139-145, 2002. (Pubitemid 44858305)
9. Cardone RA, Bellizzi A, Busco G, Weinman EJ, Dell'Aquila ME, Casavola V, Azzariti A, Mangia A, Paradiso A and Reshkin SJ: The NHERF1 PDZ2 domain regulates PKA-RhoA-p38-mediated NHE1 activation and invasion in breast tumor cells. Mol Biol Cell 18: 1768-1780, 2007. (Pubitemid 46717558)
10. Fouassier L, Rosenberg P, Mergey M, Saubaméa B, Clapéron A, Kinnman N, Chignard N, Jacobsson-Ekman G, Strandvik B, Rey C, et al: Ezrin-radixin-moesin-binding phosphoprotein (EBP50), an estrogen-inducible scaffold protein, contributes to biliary epithelial cell proliferation. Am J Pathol 174: 869-880, 2009.
11. Ledzewicz U and Schattler H: Drug resistance in cancer chemotherapy as an optimal control problem. Disease and continuous dynamical systems-series B 6: 129-150, 2006.
12. Mei M, Ren Y, Zhou X, et al: Suppression of breast cancer cells in vitro by polyamidoamine-dendrimer-mediated 5-fluorouracil chemotherapy combined with antisense micro-RNA 21 gene therapy. J Appl Polym Sci 114: 3760-3766, 2009.
13. Janát-Amsbury MM, Yockman JW, Anderson ML, Kieback DG and Kim SW: Combination of local, non-viral IL12 gene therapy and systemic paclitaxel chemotherapy in a syngeneic ID8 mouse model for human ovarian cancer. Anticancer Res 26: 3223-3228, 2006. (Pubitemid 44701489)
14. Sun Q, Zheng X, Zhang L and Yu J: Smac modulates chemosensitivity in head and neck cancer cells through the mitochondrial apoptotic pathway. Clin Cancer Res 17: 2361-2372, 2011.
15. Miyake H, Hara I, Kamidono S and Gleave ME: Novel therapeutic strategy for advanced prostate cancer using antisense oligodeoxynucleotides targeting anti-apoptotic genes upregulated after androgen withdrawal to delay androgen-independent progression and enhance chemosensitivity. Int J Urol 8: 337-349, 2001. (Pubitemid 34225114)
16. Tsujimoto Y, Finger LR, Yunis J, Nowell PC and Croce CM: Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science 226: 1097-1099, 1984. (Pubitemid 15217831)
17. Adams JM and Cory S: The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 26: 1324-1337, 2007. (Pubitemid 46328466)
18. Condorelli G, Morisco C, Stassi G, Notte A, Farina F, Sgaramella G, de Rienzo A, Roncarati R, Trimarco B and Lembo G: Increased cardiomyocyte apoptosis and changes in proapoptotic and antiapoptotic genes Bax and Bcl-2 during left ventricular adaptations to chronic pressure overload in the rat. Circulation 99: 3071-3078, 1999. (Pubitemid 29270439)
19. Duan XX, Ou JS, Li Y, Su JJ, Ou C, Yang C, Yue HF and Ban KC: Dynamic expression of apoptosis-related genes during development of laboratory hepatocellular carcinoma and its relation to apoptosis. World J Gastroenterol 11: 4740-4744, 2005. (Pubitemid 41179534)
20. Boyce M, Degterev A and Yuan J: Caspases: an ancient cellular sword of Damocles. Cell Death Differ 11: 29-37, 2004. (Pubitemid 38111370)
21. Réjiba S, Bigand C, Parmentier C and Hajri A: Gemcitabine-based chemogene therapy for pancreatic cancer using Ad-dCK::UMK GDEPT and TS/RR siRNA strategies. Neoplasia 11: 637-650. 2009.
22. Elliott MJ, Baker JD, Dong YB, Yang HL, Gleason JF Jr and McMasters KM: Inhibition of cyclin A kinase activity in E2F-1 chemogene therapy of colon cancer. Tumour Biol 23: 324-336, 2002. (Pubitemid 36566233)
23. Choi EA, Lei H, Maron DJ, Mick R, Barsoum J, Yu QC, Fraker DL, Wilson JM and Spitz FR: Combined 5-fluorouracil/systemic interferon-beta gene therapy results in long-term survival in mice with established colorectal liver metastases. Clin Cancer Res 10: 1535-1544, 2004. (Pubitemid 38365250)